<DOC>
	<DOCNO>NCT01029613</DOCNO>
	<brief_summary>Adalimumab rheumatoid arthritis . An investigation change disease activity course joint destruction use 3 Tesla Whole-Body MRI , dedicate 3 Tesla MRI CT hand , soluble biomarkers . Furthermore compare ultrasound examination wholebody MRI etc .</brief_summary>
	<brief_title>Adalimumab Rheumatoid Arthritis . An Investigation Wholebody MRI , Conventional MRI , CT Circulating Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Age &gt; 18 year old &lt; 85 year old RA accordance American College Rheumatology 1987 criterion Moderate highly active RA define DAS28 &gt; 3,2 ( CRP base ) Clinical indication TNFα inhibitor treatment treat physician No contraindication TNFα inhibitor treatment No contraindication MRI Serum creatinine normal range Sufficient contraception fertile woman Capable give informed consent Capable comply examination program protocol Other DMARDs MTX le 4 week inclusion throughout study period Cyclophosphamide , Chlorambucil alkylating agent less 4 week inclusion throughout study period Intramuscular intravenous injection glucocorticoid le 4 week inclusion throughout study period Pregnancy wish , pregnancy breastfeed Contraindications TNFα inhibitor treatment Contraindications MRI Known recent drug alcohol abuse Failure provide write consent Incapable comply examination program physical mental reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>